Trastuzumab Biosimilar: Gastric Cancer Efficacy Study
Herzuma (Trastuzumab-pkrb) in HER2+ Gastric Cancer: Real-World Efficacy and Cost-Effectiveness
Table of Contents
Herzuma (trastuzumab-pkrb) is emerging as a valuable treatment option for patients with HER2-positive advanced gastric cancer. As a biosimilar to the originator trastuzumab,Herzuma offers comparable efficacy and a more affordable price point,expanding access to this crucial therapy. This article delves into the real-world outcomes of Herzuma use in Japan, its efficacy profile, safety considerations, and its role in reducing healthcare costs.
Understanding HER2+ gastric Cancer and the role of Trastuzumab
Gastric cancer, a malignancy originating in the stomach, remains a meaningful global health challenge. A subset of these cancers, approximately 15-20%, overexpress the human epidermal growth factor receptor 2 (HER2) protein. This overexpression promotes cancer cell growth and proliferation. Trastuzumab, a monoclonal antibody targeting HER2, revolutionized the treatment landscape for HER2+ gastric cancer, substantially improving patient outcomes when combined with chemotherapy.However, the high cost of originator biologics like trastuzumab can limit patient access. Biosimilars, like Herzuma, offer a clinically equivalent option at a reduced cost, making this life-extending treatment available to a wider population.Biosimilars are not generics; they are highly similar, but not identical, to the original biologic drug. Rigorous testing ensures they deliver the same safety and effectiveness.
Real-World Evidence of Herzuma Efficacy in Japan
A recent prospective cohort study published in Oncol Ther (2025) investigated the real-world effectiveness of Herzuma in Japanese patients with HER2+ advanced gastric cancer. The study followed patients for one year after initiating Herzuma treatment, administered at the approved dosage of 8 mg/kg for the first dose, followed by 6 mg/kg every three weeks.Importantly, the study did not mandate specific chemotherapy regimens to be used in conjunction with Herzuma, reflecting real-world clinical practice.The results were encouraging. The objective response rate – the percentage of patients experiencing tumor shrinkage – was approximately 34.4%. Even more significantly, the disease control rate, encompassing both tumor shrinkage and stabilization, reached 82.4%. Median progression-free survival (PFS) – the time until the cancer begins to grow again – was approximately 7.4 months.Researchers identified several factors associated with shorter PFS, including:
Gastroesophageal junction cancer
presence of three or more metastases
Lack of prior gastrectomy (stomach removal surgery)
Prior chemotherapy exposure
Lack of prior platinum-based chemotherapy
These findings help clinicians identify patients who may benefit from closer monitoring or alternative treatment strategies.
Safety Profile and Adverse Events
The study confirmed that Herzuma’s safety profile is consistent with that of the originator trastuzumab. Adverse events were reported in 88.3% of patients, with 32.3% experiencing grade 3 or higher severity events. Common adverse events included:
Infusion Reactions: Occurring in 12.3% of patients.
Cardiac Disorders: Four cases were reported, two involving mild cardiac dysfunction and two involving severe ischemic heart disease. Careful cardiac monitoring is crucial during treatment.
Interstitial Lung Disease: Reported in 2.3% of patients, highlighting the importance of respiratory symptom monitoring.
The study authors concluded that Herzuma presented “no new safety issues” and demonstrated “sufficient efficacy” in diverse treatment settings.
Cost-Effectiveness and Access to treatment
A key advantage of Herzuma is its cost-effectiveness. In Japan, government regulations incentivize the use of biosimilars to reduce healthcare expenditures. As a result, Herzuma is priced lower than the originator trastuzumab, making it a financially viable option for both patients and healthcare systems. This affordability expands access to a potentially life-saving treatment for a greater number of individuals with HER2+ advanced gastric cancer.
The Future of Herzuma and Biosimilars in Cancer Care
The growing body of real-world evidence supporting the efficacy and safety of Herzuma, coupled with its cost advantages, positions it as a crucial component of modern cancer care. As more biosimilars become available, they are poised to play